adalimumab (Humira®)

Reference No. 2571

Publication date:

10/12/2015

Appraisal information

adalimumab (Humira®) 40 mg/0.8 ml solution for injection

Company:	AbbVie Ltd
BNF category:	Skin
NMG meeting date:	07/10/2015
AWMSG meeting date:	11/11/2015

Submission Type:	Limited Submission
Status:	Superseded
Advice No:	3615
Ministerial ratification:	09/12/2015

Current Progress

Submission
received

NMG
meeting

AWMSG
meeting

Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA455) NICE GUIDANCE ISSUED JULY 2017 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

Final Appraisal Recommendation (FAR)

Download

adalimumab (Humira) 2571 FAR

AWMSG Secretariat Appraisal Report (ASAR)

Download

adalimumab (Humira) 2571 ASAR

Clinical Expert (CE) Summary

Download

adalimumab (Humira) 2571 CE Summary